Segment Information - Schedule of Reconciliation to the Consolidated Net Loss (Details) - Operating Segment [Member] - USD ($) |
12 Months Ended | |||||||
|---|---|---|---|---|---|---|---|---|
Dec. 31, 2024 |
Dec. 31, 2023 |
|||||||
| Significant segment expenses | ||||||||
| General and administrative | [1] | $ 5,786,293 | $ 6,306,707 | |||||
| Pre-clinical research | [1] | 1,479,896 | 3,584,483 | |||||
| CMC | [1] | 1,463,530 | 2,490,729 | |||||
| Clinical development | [1] | 4,097,521 | 1,652,808 | |||||
| License milestone payments | 250,000 | |||||||
| Depreciation and amortization | 649,029 | 648,454 | ||||||
| Share based compensation expense | 773,693 | 592,269 | ||||||
| Other segment items | [2] | 453,911 | ||||||
| Total operating and segment expenses | 14,249,962 | 15,979,361 | ||||||
| Change in fair value of warrant liabilities | 77,806 | (56,245) | ||||||
| Interest and dividends, net | (423,184) | (415,368) | ||||||
| Adjustments and reconciling items | [3] | 453,910 | ||||||
| Segment and consolidated net loss | $ 13,904,584 | $ 15,961,658 | ||||||
| ||||||||
| X | ||||||||||
- Definition Adjustments and reconciling items. No definition available.
|
| X | ||||||||||
- Definition The amount of cmc. No definition available.
|
| X | ||||||||||
- Definition Amount of clinical development. No definition available.
|
| X | ||||||||||
- Definition The amount of Llcense milestone payments. No definition available.
|
| X | ||||||||||
- Definition The amount of pre-clinical research. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The amount of operating and segment expenses. No definition available.
|
| X | ||||||||||
- Definition Amount, after tax, of expense for award under share-based payment arrangement. No definition available.
|
| X | ||||||||||
- Definition The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of expense (income) related to adjustment to fair value of warrant liability. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss). Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Details
|